Cathepsin E Protein (CTSE) (AA 18-396)

Catalog No. ABIN2667383

Recombinant Cathepsin E protein expressed in Escherichia coli (E. coli).

Quick Overview for Cathepsin E Protein (CTSE) (AA 18-396) (ABIN2667383)

Target: Cathepsin E (CTSE)

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: Escherichia coli (E. coli)

Application: Intracellular Flow Cytometry (ICFC)

Purity: >95 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 18-396

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: After auto-activation, CTSE activity is determined by its ability to cleave the fluorogenic peptide substrate, Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2. The specific activity is >1,500 pmol/min/μg.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening.

Buffer: 0.22 μm filtered protein solution is in 20 mM MES, 150 mM NaCl, pH 6.5.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored at -70°C for six months.

Target Details

Target: Cathepsin E (CTSE)

Alternative Name: Cathepsin E

Background: Cathepesin E (CTSE) is an intracellular aspartic protease that was originally identified as a cathepsin D-like acid protease. CTSE and CTSD have similar substrate specificities and CTSE is active in acidic conditions in a pH range from 2.5 to 5.5. In vitro experiments have identified several CTSE substrates including insulin beta chain, neurokinin, and FGF. Although the function of CTSE is not completely understood, it has been implicated in several physiological and pathological processes. CTSE is required for antigen presentation on class II MHC molecules and subsequently, CTSE-deficient mice have increased susceptibility to bacterial infections. CTSE-deficient macrophages also show abnormalities, such as autophagy. Like many other cathepsins, CTSE has emerged as a therapy target for cancers, such as pancreatic ductal adenocarcinoma (PDAC). In addition to PDAC, CTSE is also overexpressed in gastric carcinomas and cervical and lung adenocarcinomas. The possible involvement of CTSE in neurodegeneration has also been reported.

Molecular Weight: The 389 amino acid recombinant protein has a predicted molecular mass of approximately 42.3 kDa. The DTT-reduced protein migrates at approximately 45 kDa and the non-reduced protein migrates at approximately 90 kDa by SDS-PAGE. The N-terminal amino acid i